CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein ( GFAP ) autoimmunity
Annals of Clinical and Translational Neurology · 2025-04 · 12 (4) · 855-860
DOI: 10.1002/acn3.52305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 27.01.2025. Verfasst von Yahel Segal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Cytokines, Chemokines, Autoimmunity. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AOU NIH HHS, NINDS NIH HHS, Center for MS and Autoimmune Neurology, Mayo Clinic.
Abstract (Originalsprache)
Defining the CSF cytokine/chemokine and injury biomarker signature of glial fibrillary acidic protein (GFAP) autoimmunity can inform immunopathogenesis. CSF GFAP‐IgG‐positive samples ( N = 98) were tested for 17 cytokines/chemokines, neurofilament light chain (NfL), and GFAP (ELLA, Bio‐Techne). Controls included non‐inflammatory ( N = 42), AQP4‐IgG‐positive ( N = 83), CNS infections ( N = 13), and neurosarcoidosis ( N = 32). IL5, IL6, IL10, IL8/CXCL8, CXCL9, CXCL10, CXCL13, BAFF, GM‐CSF, IFN‐gamma, and TNF‐alpha concentrations were higher compared to non‐inflammatory controls ( P < 0.01). GFAP concentrations were similar to those of AQP4‐IgG‐positive patients; NfL was higher ( P < 0.001) and correlated with MRI changes and outcomes. CSF cytokine/chemokine findings in GFAP autoimmunity correlate with histopathology; GFAP and NfL hold promise as disease biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Roche Product Development-Neuroscience, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
ORCID-Profile: Yahel Segal, Divyanshu Dubey, Andrew McKeon, Sean J Pittock, Anastasia Zekeridou
Förderung
- AOU NIH HHS
- NINDS NIH HHS
- Center for MS and Autoimmune Neurology, Mayo Clinic
- Genentech
- Mayo Clinic
- All of Us Research Program
Zitieren
APA
Segal, Y., Mangioris, G., Lennon, V., Yang, B., Dubey, D., Flanagan, E. P., McKeon, A., Mills, J. R., Toledano, M., Vodopivec, I., Pittock, S. J., & Zekeridou, A. (2025). CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein ( GFAP ) autoimmunity. Annals of Clinical and Translational Neurology, 12(4), 855-860. https://doi.org/10.1002/acn3.52305
Vancouver
Segal Y, Mangioris G, Lennon V, Yang B, Dubey D, Flanagan EP, et al. CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein ( GFAP ) autoimmunity. Annals of Clinical and Translational Neurology. 2025;12(4):855-860. doi:10.1002/acn3.52305
BibTeX
@article{Segal2025,
author = {Segal, Yahel and Mangioris, Georgios and Lennon, Vanda and Yang, Binxia and Dubey, Divyanshu and Flanagan, Eoin P and McKeon, Andrew and Mills, John R and Toledano, Michel and Vodopivec, Ivana and Pittock, Sean J and Zekeridou, Anastasia},
title = {CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein ( GFAP ) autoimmunity},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
volume = {12},
number = {4},
pages = {855--860},
doi = {10.1002/acn3.52305}
}
EUVIMED